SYN
Synthetic Biologics Inc
Price:  
1.02 
USD
Volume:  
57,789.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

SYN WACC - Weighted Average Cost of Capital

The WACC of Synthetic Biologics Inc (SYN) is 8.8%.

The Cost of Equity of Synthetic Biologics Inc (SYN) is 8.85%.
The Cost of Debt of Synthetic Biologics Inc (SYN) is 5.00%.

Range Selected
Cost of equity 7.70% - 10.00% 8.85%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 7.6% - 9.9% 8.8%
WACC

SYN WACC calculation

Category Low High
Long-term bond rate 4.2% 4.7%
Equity market risk premium 5.0% 6.0%
Adjusted beta 0.7 0.8
Additional risk adjustments 0.0% 0.5%
Cost of equity 7.70% 10.00%
Tax rate 26.20% 27.00%
Debt/Equity ratio 0.02 0.02
Cost of debt 5.00% 5.00%
After-tax WACC 7.6% 9.9%
Selected WACC 8.8%

SYN's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for SYN:

cost_of_equity (8.85%) = risk_free_rate (4.45%) + equity_risk_premium (5.50%) * adjusted_beta (0.7) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.